Zynex Announces Multi-Million Dollar NIH Grant to Fund Four-Year Study of Company's NeuroMove(TM) Stroke Recovery System.

LITTLETON, Colo. -- Zynex Medical Holdings, Inc. (OTCBB: ZYNX), a provider of pain management systems and electrotherapy products for medical patients with functional disability, today announced that the National Institutes of Health (NIH) has awarded a multi-million dollar grant to fund a multicenter, randomized study of the Company's NeuroMove(TM) technology for acute stroke victims.

The four-year study, entitled "Electrical Stimulation of Upper Limb Recovery in Stroke," is being conducted in collaboration with Case Western Reserve University and the University of Cincinnati, both of which will be collecting patient data. The patients will be followed for six months and outcome measures will include motor impairment, upper limb specific activity limitation and EMG activation patterns. The study is scheduled to include a total of 189 patients over a period of four years and the results will be published after all patients have been evaluated.

"While there have been many clinical studies done on our technology, this is the first extensive study to further demonstrate the effectiveness of the NeuroMove(TM) specifically in comparison to just sensory activation as well as passive electrical stimulation. We are excited to support this research study and we have already received the first of several orders to supply units for the researchers", stated President and Chief Executive Officer Thomas Sandgaard.

The NeuroMove(TM) is cleared by the U.S. Food and Drug Administration (FDA) for Stroke Rehabilitation, and was introduced to the market in 2003. .The NeuroMove requires a doctor's prescription and targets the four million stroke survivors in the U.S. alone who live with some degree of reduced mobility.

The NeuroMove(TM) system increases the functionality of many stroke victims by teaching the healthy parts of the brain to compensate for damaged areas. The NeuroMove(TM), which is more sensitive than most diagnostic equipment, monitors muscle activity and selects signals from the brain indicating that the patient is attempting to move a certain muscle. It then introduces the actual movement through electrical stimulation. Eventually the connection between the brain and muscle can often be reestablished. The NeuroMove(TM) (www.neuromove.com) also can be used to treat spinal cord injuries.

About Zynex

Zynex Medical Holdings, Inc., (www.zynexmed.com), a leading provider of therapeutic devices for patients with functional disability through the creation, distribution, and marketing of electrotherapy devices since 1996, strives to uphold its mission to improve the quality of life of patients suffering from debilitating pain or illness by providing innovative technology. Utilizing a unique combination of electromyographic (EMG) technology combined with a system of instruction and reinforcement, including electrical muscle stimulation (EMS), Zynex offers new treatment options to post-stroke and spinal injury patients.

Safe Harbor Provision

Certain statements in this release are "forward-looking" and as such are subject to numerous risks and uncertainties. Actual results may vary significantly from the results expressed or implied in such statements. Factors that could cause actual results to materially differ from forward-looking statements include, but are not limited to, the Company's ability to meet terms and conditions required to obtain project financing, risks and delays associated with product development, risk of market acceptance of new products, technology or product obsolescence, competitive risks, reliance on development partners and additional capital needs. For more discussion of important risk factors that may affect Zynex, please see the risk factors contained in Zynex's 2004 Annual Report on Form 10-K filed with the Securities and Exchange Commission.